Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study

Journal of Psychiatric Research

Volumn 43, Issue 3, 2009, Pages 265-273

  Haro, Josep Maria ^a   Novick, Diego ^b   Suarez, David ^a   Roca, Mercedes ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Olanzapine; Schizophrenia; Treatment discontinuation

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GALACTORRHEA; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONFIDENCE INTERVALS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57849125864     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.06.001     Document Type: Article

References (40)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
2. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia (2nd ed.). American Journal of Psychiatry 2004;161 (Suppl. 2):1-56.
3. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., and Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6 (2006) 8
4. Beasley C.M., Stauffer V.L., Liu-Seifert H., Taylor C.C., Dunayevich E., and Davis J.M. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis. Journal of Clinical Psychopharmacology 27 (2007) 252-258
5. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., Garcia-Portilla M.P., Fernandez I., et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research 62 (2003) 77-88
6. Cooper D., Moisan J., Gaudet M., Abdous B., and Gregoire J.P. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Canadian Journal of Psychiatry 50 (2005) 901-908
7. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 158 (2001) 765-774
8. Covell N.H., Jackson C.T., Evans A.C., and Essock S.M. Antipsychotic prescribing practices in Connecticut's Public Mental Health System: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28 (2002) 17-29
9. Cutler A.J., Goldstein J.M., and Tumas J.A. Dosing and switching strategies for quetiapine fumarate. Clinical Therapeutics 24 (2002) 209-222
10. Curran M.P., and Perry C.M. Spotlight on amisulpride in schizophrenia. CNS Drugs 16 (2002) 207-211
11. Gilbert P.L., Harris M.J., McAdams L.A., and Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 52 (1995) 173-188
12. Gitlin M., Nuechterlein K., Subotnik K.L., Ventura J., Mintz J., Fogelson D.L., et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry 158 (2001) 1835-1842
13. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research 86 (2006) 234-243
14. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology, revised (1976), National Institute of Mental Health, Rockville (MD)
15. Hafner H., and An der Heiden W. Epidemiology of schizophrenia. Canadian Journal of Psychiatry 42 (1997) 139-151
16. Halbreich U., Kinon B.J., Gilmore J.A., and Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 Suppl. 1 (2003) 53-67
17. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fragas A., et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica 107 416 (2003) 16-23
18. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica 107 (2003) 222-223
19. Haro J.M., Kontodimas S., Negrin M.A., Ratcliffe M., Suarez D., and Windmeijer F. Methodological aspects in the assessment of treatment effects in observational health outcome studies. Applied Health Economics and Health Policy 5 (2006) 11-25
20. Haro J.M., Novick D., Suarez D., Alonso J., Lepine J.P., Ratcliffe M., et al. Remission and relapse in the outpatient care of schizophrenia. Three-year results from the Schizohprenia Outpatient Health Outcomes Study. Journal of Clinical Psychopharmacology 26 (2006) 571-578
21. Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. European Neuropsychopharmacology 17 (2007) 235-244
22. Kinon B.J., Liu-Seifert H., Adams D.H., and Citrome L. Differential rate of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. Journal of Clinical Psychopharmacology 26 (2006) 532-537
23. Lambert M., Haro J.M., Novick D., Edgell E.T., Kennedy L., Ratcliffe M., et al. Olanzapine versus other antipsychotics in actual outpatient settings: 6-month safety results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatrica Scandinavica 111 (2005) 232-243
24. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35 (1999) 51-68
25. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
26. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164 (2007) 1050-1060
27. Milev P., Ho B.C., Arndt S., and Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry 162 (2005) 495-506
28. National Institute for Clinical Excellence (NICE). Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: NICE; 2002.
29. Remington G. Rational pharmacotherapy in early psychosis. British Journal of Psychiatry 187 48 (2005) 77-84
30. Ren X.S., Qian S., Lee A.F., Herz L., Miller D.R., and Kazis L.E. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. Journal of Clinical Pharmacy and Therapeutics 31 (2006) 57-65
31. Robinson D., Woerner M.G., Alvir J.M.J., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56 (1999) 241-247
32. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., and Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 57 (2002) 209-219
33. Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., and Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161 (2004) 473-479
34. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 162 (2005) 947-953
35. Tarsy D., Baldessarini R.J., and Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16 (2002) 23-45
36. Tiihonen J., Walhbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P.A., Volavka J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation die to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333 (2006) 224-229
37. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration study. American Journal of Psychiatry 154 (1997) 457-465
38. Tunis S.L., Faries D.E., Stensland M.D., Hay D.P., and Kinon B.J. An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. Current Medical Research and Opinion 23 (2007) 97-104
39. Turrone P., Kapur S., Seeman M.V., and Flint A.J. Elevation of prolactin levels by atypical antipsychotics. American Journal of Psychiatry 159 (2002) 133-135
40. Wyatt T.J., and Henter I.D. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. Journal of Psychiatric Research 32 (1998) 169-177